Calcitriol Treatment Increases Serum Levels of the Soluble Receptor of Advanced Glycation End Products in Hemodialysis Patients with Secondary Hyperparathyroidism
-
- Sung Ji Yoon
- Division of Nephrology, Department of Internal Medicine, Gachon University of Gil Medical Center, Gachon University of Medicine and Science
-
- Chung Wookyung
- Division of Nephrology, Department of Internal Medicine, Gachon University of Gil Medical Center, Gachon University of Medicine and Science
-
- Kim Ae Jin
- Division of Nephrology, Department of Internal Medicine, Gachon University of Gil Medical Center, Gachon University of Medicine and Science
-
- Kim Hyung Soo
- Division of Nephrology, Department of Internal Medicine, Gachon University of Gil Medical Center, Gachon University of Medicine and Science
-
- Ro Han
- Division of Nephrology, Department of Internal Medicine, Gachon University of Gil Medical Center, Gachon University of Medicine and Science
-
- Chang Jae Hyun
- Division of Nephrology, Department of Internal Medicine, Gachon University of Gil Medical Center, Gachon University of Medicine and Science
-
- Lee Hyun Hee
- Division of Nephrology, Department of Internal Medicine, Gachon University of Gil Medical Center, Gachon University of Medicine and Science
-
- Jung Ji Yong
- Division of Nephrology, Department of Internal Medicine, Gachon University of Gil Medical Center, Gachon University of Medicine and Science
この論文をさがす
抄録
Cardiovascular disease is common in the patients with end-stage renal disease, who often suffer from secondary hyperparathyroidism (SHP). Vitamin D is considered for the first-line therapy managing SHP in hemodialysis (HD) patients and has a beneficial effect in the chronic inflammation and development of cardiovascular disease. The soluble receptor for advanced glycation end products (sRAGE) may be protective by binding AGE in the pathogenesis of atherosclerotic vascular complications, whereas extracellular RAGE-binding protein (EN-RAGE) represents pro-inflammatory ligands for RAGE. We have hypothesized that vitamin D treatment may alter the levels of sRAGE and EN-RAGE in HD patients. Therefore, this prospective observational study was performed in 51 HD patients with SHP who had low serum 1,25 dihydroxyvitamin D3 (1,25D) levels and elevated intact parathyroid hormone (PTH) levels. We evaluated the changes in the values of sRAGE, EN-RAGE, and other inflammatory marker, interleukin-6 (IL-6), before and at the end of the 8-week calcitriol treatment. After calcitriol treatment, the serum levels of 1,25D were increased, whereas the serum intact PTH levels were decreased. In addition, the sRAGE levels were increased, whereas those of IL-6 were decreased after calcitriol treatment. A positive correlation between 1,25D and sRAGE levels (r = 0.609, P < 0.001) and a negative correlation between sRAGE and EN-RAGE levels (r = −0.368, P = 0.020) were detected after calcitriol treatment. This study suggests that calcitriol treatment could play an anti-inflammatory role through the increasing sRAGE in HD patients with SHP.
収録刊行物
-
- The Tohoku Journal of Experimental Medicine
-
The Tohoku Journal of Experimental Medicine 230 (1), 59-66, 2013
東北ジャーナル刊行会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282679221453952
-
- NII論文ID
- 10031175420
-
- NII書誌ID
- AA00863920
-
- COI
- 1:CAS:528:DC%2BC3sXhtFygs7bJ
-
- ISSN
- 13493329
- 00408727
-
- PubMed
- 23748365
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可